This randomized phase II trial studies how well carboplatin and paclitaxel with or without
panitumumab work in treating patients with invasive triple negative breast cancer. Drugs used
in the chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the
growth of tumor cells, either by killing the cells, by stopping the them from dividing, or by
stopping them from spreading. Monoclonal antibodies, such as panitumumab, may interfere with
the ability of tumor cells to grow and spread. Giving carboplatin and paclitaxel with or
without panitumumab before surgery may make the tumor smaller and reduce the amount of normal
tissue that needs to be removed.